Sanofi (France)
NEWS
Paris-based Sanofi announced its Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit primary or key secondary endpoints.
The acquisition expands Sanofi’s General Medicines core assets and highlights the addition of Rezurock (belumosudil) to its transplant portfolio.
The analysis showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate with patients having nasal polyps, and 52% in patients not having nasal polyps.
Sanofi has announced that the U.S. FDA approved its new treatment for children one year of age or older diagnosed with late-onset Pompe disease.
The Phase III trial shows that PD-1 inhibitor Libtayo and platinum-doublet chemotherapy significantly improved OS compared with chemotherapy alone with locally advanced NSCLC.
With its acquisition, Sanofi aims to establish a firm toehold in the mRNA space by integrating dedicated research and development capabilities, chemistry, manufacturing and controls.
Topline results from a late-stage trial show Regeneron Pharmaceuticals and Sanofi’s Dupixent reduced itch in biologic-naiïve patients with chronic spontaneous urticaria.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The trial is the third study in a set of pivotal trials to report positive data for the therapy.
JOBS
IN THE PRESS